Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy

The latest update is out from Eton Pharmaceuticals ( (ETON) ).

On February 25, 2026, Eton Pharmaceuticals announced U.S. FDA approval of DESMODA, the first and only FDA-approved desmopressin oral solution, for management of central diabetes insipidus as antidiuretic replacement therapy in adults and children. Designed as a ready-to-use 0.05 mg/mL liquid, DESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing in a rare disease where fine titration is critical to maintaining water balance.

The company estimates more than 13,000 U.S. patients, including 3,000–4,000 pediatric cases, could be eligible for treatment and projects DESMODA’s peak annual sales at $30–50 million, with patent protection through 2044. Commercial launch is expected on March 9, with promotion through Eton’s existing pediatric endocrinology sales platform and distribution exclusively via specialty pharmacy Anovo, supported by the Eton Cares access program that offers benefits investigation, education, and co-pay assistance for qualifying patients.

The most recent analyst rating on (ETON) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Eton Pharmaceuticals stock, see the ETON Stock Forecast page.

Spark’s Take on ETON Stock

According to Spark, TipRanks’ AI Analyst, ETON is a Neutral.

ETON scores as moderately attractive primarily due to improving fundamentals—strong revenue acceleration, robust operating/free cash flow, and a de-risked balance sheet—supported by a generally positive earnings-call outlook on growth and margins. The score is held back by weak technical trends and the lack of current profitability (negative earnings and net losses), with valuation less supportive due to negative EPS and no dividend yield.

To see Spark’s full report on ETON stock, click here.

More about Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly in endocrine and metabolic disorders. The company currently markets nine rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, and has four additional late-stage product candidates.

Average Trading Volume: 236,373

Technical Sentiment Signal: Strong Buy

Current Market Cap: $490.2M

Find detailed analytics on ETON stock on TipRanks’ Stock Analysis page.